国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Eisai China Inc. (hereinafter referred to as “Eisai China”) successfully held the launch meeting of Fycompa? (perampanel) in China on December 1, 2019, which marks the official launch of the new third-generation antiepileptic drug of Fycompa??in China. This means that the first non-competitive AMPA receptor antagonist is officially ushered in the field of epilepsy treatment in China, which will bring new treatment methods and means for the majority of patients with epilepsy and their families.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa?) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.

Cambridge, Mass. and Tokyo, Japan – October 22, 2019 –?Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease (AD).

Eisai Co.,?Ltd.?(Headquarters: Tokyo, CEO: Haruo Naito,?“Eisai”)?announced today thatEisai received?a?New Drug Approval for?its in-house?discovered?and?developed?antiepileptic drug (AED)?Fycompa??(perampanel)?from the China National Medical Products Administration (NMPA) for use in?an adjunctive?treatment?of?partial onset seizures?(with or without secondarily generalized seizures)in epilepsy patients?12 years of age and older.?Fycompa?was?designated for Priority Review by?the?NMPA?due to?itssignificant?clinical benefits?compared to existing treatments,?and?was?approved in about 12?months since?the?submission in?September?2018.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Nichi-Iko Pharmaceutical (Headquarters: Toyama, President and CEO: Yuichi Tamura, “Nichi-Iko”) announced today that they have entered into a comprehensive collaboration agreement (hereinafter, “agreement”) for the generic pharmaceutical business in China.